Action BRPA NRX PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues NRx Pharmaceuticals, Inc.

Actions

BRPA

US6294442099

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 15/07/2024 		Varia. 5j. Varia. 1 janv.
2,39 USD -3,63 % Graphique intraday de NRx Pharmaceuticals, Inc. +3,02 % -48,04 %
28/06 NRx Pharmaceuticals, Inc. va procéder à deux demandes de nouveaux médicaments en 2024 CI
27/06 Nrx Pharmaceuticals, Inc. Reçoit un avis de résiliation de l'accord mondial exclusif de développement, d'approvisionnement, de commercialisation et de licence conclu entre Alvogen, Inc. de développement, d'approvisionnement, de commercialisation et de licence entre Alvogen, Inc, Alvogen Pharma Us, Inc et Lotus Pharmaceutical Co. Ltd CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
NRx Pharmaceuticals Publishes Shareholder Update Letter
NRx Pharmaceuticals to Proceed with Two New Drug Applications in 2024, NRX-101 has Been Returned to the Company for Filing
NRx Pharmaceuticals, Inc. to Proceed with Two New Drug Applications in 2024
Nrx Pharmaceuticals, Inc. Receives A Notice of Termination of Exclusive, Global ? Development, Supply, Marketing & License Agreement by and Between Alvogen, Inc., Alvogen Pharma Us, Inc. and Lotus Pharmaceutical Co. Ltd
NRx Pharmaceuticals Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors
NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors
Certain Warrant of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-JUN-2024.
Certain Common Stock of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-JUN-2024.
NRx Pharmaceuticals Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression at the American Society of Clinical Psychopharmacology Annual Meeting
NRx Pharmaceuticals, Inc. Presents Landmark Trial of Nrx-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: Nrx-101 Is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression
Certain Warrants of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-MAY-2024.
Certain Option awards of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-MAY-2024.
Certain Common Stock of NRx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 28-MAY-2024.
NRx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
NRx Pharmaceuticals, Inc. to Participate in the EF Hutton Annual Global Conference on May 15, 2024
NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data
NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results
NRx Pharmaceuticals : Notice of Acceleration - Form 8-K
NRx Pharmaceuticals Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BRPA
  4. Actualités NRx Pharmaceuticals, Inc.
  5. Autres langues